When treating a patient with suspected ACS, the goal is to deliver a rapid, reliable antiplatelet effect. Chewable aspirin that is non-enteric coated is preferred because chewing increases the surface area for absorption, giving a quicker onset than swallowing a tablet whole. The total dose should be around 160–325 mg. The best option matches that goal by delivering about 324 mg of aspirin through chewed administration: either one 325 mg chewable tablet or four 81 mg chewable tablets. Both achieve the recommended total dose quickly and maximize absorption. Giving only 81 mg chewed would provide too small a dose to achieve prompt antiplatelet effect. Swallowing a 325 mg tablet whole is less ideal in the ACS setting because it delays absorption compared with chewing. A much higher dose, like 1625 mg, is unnecessary and increases the risk of adverse effects without additional benefit.